Nepsis Inc. Lowers Stock Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Nepsis Inc. reduced its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 95.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 96,257 shares of the company's stock after selling 2,008,271 shares during the quarter. Health Catalyst comprises about 0.1% of Nepsis Inc.'s portfolio, making the stock its 26th biggest position. Nepsis Inc. owned approximately 0.16% of Health Catalyst worth $681,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Millennium Management LLC raised its holdings in shares of Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company's stock worth $15,421,000 after acquiring an additional 1,184,131 shares during the last quarter. Fred Alger Management LLC purchased a new stake in shares of Health Catalyst in the third quarter worth approximately $6,858,000. Portolan Capital Management LLC purchased a new stake in shares of Health Catalyst in the third quarter worth approximately $5,402,000. Impax Asset Management Group plc boosted its position in shares of Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company's stock valued at $20,793,000 after buying an additional 360,201 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Health Catalyst during the third quarter valued at approximately $2,012,000. Institutional investors own 85.00% of the company's stock.

Wall Street Analysts Forecast Growth

HCAT has been the topic of several recent analyst reports. Evercore ISI raised their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Tuesday, October 8th. Canaccord Genuity Group dropped their price target on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. KeyCorp raised shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 target price on the stock in a research report on Wednesday, January 8th. Finally, Piper Sandler restated an "overweight" rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $10.91.

Health Catalyst Stock Performance

Health Catalyst stock traded down $0.02 during midday trading on Friday, reaching $5.77. The stock had a trading volume of 469,410 shares, compared to its average volume of 691,851. The firm has a market capitalization of $351.10 million, a PE ratio of -4.27 and a beta of 1.36. Health Catalyst, Inc. has a 12 month low of $5.35 and a 12 month high of $10.99. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm's 50-day moving average price is $7.30 and its 200 day moving average price is $7.50.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. The business's quarterly revenue was up 3.5% compared to the same quarter last year. As a group, research analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Duncan Gallagher sold 4,500 shares of the business's stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total transaction of $31,410.00. Following the completion of the transaction, the director now directly owns 74,438 shares in the company, valued at $519,577.24. The trade was a 5.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Daniel Lesueur sold 5,209 shares of the company's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the transaction, the chief operating officer now directly owns 129,690 shares in the company, valued at approximately $998,613. The trade was a 3.86 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,169 shares of company stock worth $639,174. 2.50% of the stock is owned by corporate insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.